The randomized phase II GRIFFIN study showing that the addition of Darzalex (daratumumab) to bortezomib, lenalidomide, and dexamethasone induced higher response rates in newly diagnosed patients with multiple myeloma who were eligible for high-dose therapy and autologous stem cell transplantation compared with VRd alone.
The NCI Human Tumor Atlas Network (HTAN) has published a cluster of papers intended to advance the framework of spatial omics, the science of profiling morphological and molecular features of human cancers in two and three dimensions.
